dasatinib / Generic mfg. - LARVOL DELTA

Imatinib in chronic myeloid leukemia: A comparative assessment of patients in pivotal clinical trials and real-world settings (ASH 2025) - " We included the imatinib arm of 5 pivotal CTs: the IRIS, which established the superiority of imatinib over interferon alfa plus cytarabine, and the DASISION, ENESTnd, BFORE, and ASC4FIRST trials, which supported the approvals of dasatinib, nilotinib, bosutinib, and asciminib, respectively. Patients in the RWD cohort exhibited higher clinical risk profiles, greater racial and ethnic diversity, and longer intervals between diagnosis and treatment initiation. These factors may contribute to the lower rates of achieving optimal treatment responses, including cytogenetic and molecular milestones. Despite these differences, long-term outcomes were comparable, aligning with current trends showing that survival in CML patients now approaches that of the general population."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Model-based evaluation of clinical outcomes for ponatinib versus 2G TKIs in third-line chronic myeloid leukemia (CML) (ASH 2025) - "Objectives: To estimate and compare ponatinib versus 2G TKIs (bosutinib, dasatinib, nilotinib) in adult patients with CP-CML who have received two prior TKIs, focusing on long-term clinical and economic outcomes: survival (life years), quality-adjusted survival (QALYs), and healthcare resource utilization (outpatient, inpatient and emergency department visits). This model-based analysis suggests that ponatinib offers substantial clinical benefits over 2G TKIs in the third-line treatment of CP-CML, particularly for patients with the T315I mutation. These findings support the clinical value of ponatinib as a preferred treatment option in this setting, with the potential to improve survival outcomes and reduce burden to the healthcare system."

Clinical • Clinical data • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia

Timing of tyrosine kinase inhibitor switching and long-term outcomes in chronic myeloid leukemia: A real-world comparative study (ASH 2025) - "This study evaluates the comparative safety and effectiveness of early switching (<3 months), late switching (≥6 months), and continued first-line TKI therapy across imatinib, dasatinib, and nilotinib. Switch timing in CML has substantial prognostic implications. Early TKI switching, especially within the first 3 months, is associated with higher mortality and complications. Late switching may be better tolerated, particularly with second-generation agents."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Malignancies • Leukemia • Metabolic Disorders

Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor (ASH 2025) - "Specifically, dasatinib was administered to four patients, while olverembatinib for three patients...Prophylaxis for graft-versus-host disease (GVHD) routinely included cyclosporine A and mycophenolate mofetil, with or without methotrexate... Prompt HSCT for de novo CML-BP, combined with early TKI maintenance post-transplantation, appears to contribute to effective disease management. Additionally, unrelated cord blood donors seem to provide a viable source for transplantation. Furthermore, olverembatinib has demonstrated favorable safety and efficacy profiles both pre- and post-transplantation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • ABL1

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center (ASH 2025) - "Treatment options included ciltacabtagene autoleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel...Secondary outcomes included use of tocilizumab, corticosteroids, vasopressors, anakinra, intrathecal chemotherapy, dasatinib, and thiamine; length of stay; survival at 100 days and 1 year... 53 patients were included in the study. Most patients receiving axi-cel experienced grade 1 or 2 CRS, with only three patients experiencing grade ≥3 CRS. The incidence of CRS was lower here compared to ZUMA-1 and ZUMA-5."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: A multi-center study in China (ASH 2025) - "In MLN with PDGFRA fusion genes, 22 patients in chronic phase(CP) were treated with imatinib, 1 patient with AML received chemotherapy + imatinib, and 1 patient with ALL received dasatinib + chemotherapy. The clinical manifestations of MLN-TK are different, which may involve multiple organs. The increase of eosinophils is more common, and the prognosis of BP or secondary BP seems to be worse."

Clinical • Bone Marrow Transplantation • Eosinophilia • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Plasma Cell Leukemia • Sarcoma • Solid Tumor • ABL1 • ALK • ETV6 • FGFR1 • FLT3 • JAK2 • PDGFRA • PDGFRB • RANBP2 • RUNX1 • ZMYM2

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission (ASH 2025) - P2 | "Patients who did not achieve MR4.5 after 24 months on asciminib, experienced treatment failure at any time or had a warning response at 12 months were offered the addition of lowTKI (imatinib 300 mg, dasatinib 50 mg or nilotinib 300 mg daily). Asciminib monotherapy demonstrated rapid early and deep molecular responses in patients with CP-CML, with a favorable safety profile. Further data will be presented for patients who added lowTKI."

Clinical • Chronic Myeloid Leukemia • CNS Disorders • Dermatology • Hypertension • Insomnia • Musculoskeletal Pain • Neutropenia • Pancreatitis • Sleep Disorder • Thrombocytopenia • ABL1

A case of delayed transformation to lymphoid blast crisis in a patient with chronic myeloid leukemia (ASH 2025) - "She was transitioned to nilotinib, followed by dasatinib due to cardiac side effects...Although this patient experienced resistance to imatinib early in her course and required three different TKI therapies, she had a major molecular response on dasatinib for over 10 years...Furthermore, the rate of transformation from CML to ALL is much less frequent than transformation from CML to AML, with the risk of transformation dramatically declining after 5 years of starting TKI therapy. This case highlights how a rare CML patient with an MMR may still go on to blast phase disease."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • BCR • CD20 • CD34 • CD79A • MME

Erythroblastic sarcoma transformation from chronic myeloid leukaemia: A case report (ASH 2025) - "Dasatinib was held due to concerns of drug-related pleural effusion and disease progression...She received three cycles of high-dose cytarabine and ponatinib...She continues to receive ponatinib with plans to add Azacitidine... Myeloid Sarcoma is a rare form of myeloid malignancies, which is usually composed of myeloblasts, Monoblasts or megakaryoblasts. Erythroblastic sarcoma is a rare form of MS which is associated with a poor prognosis. ES Transformation from CML is extremely rare, with only a few cases reported in the literature."

Case report • Clinical • IO biomarker • Acute Myelogenous Leukemia • Cardiovascular • Chronic Myeloid Leukemia • Hematological Malignancies • Hypertension • Leukemia • Lymphoma • Musculoskeletal Pain • Respiratory Diseases • Sarcoma • Solid Tumor • ABL1 • BCR • CD123 • CD33 • CD36 • CD38 • CD7 • IL3RA • KIT • SCARB1 • TFRC

Chronic myeloid leukemia and ASXL1 mutations: A distinct entity requiring special attention (ASH 2025) - "Initial treatment: nilotinib 800 mg/day, reduced to 200 mg BID due to hematologic toxicity...Started 7+3 (cytarabine + daunorubicin) + ponatinib on 05/20/2025...NGS:WT1 p.C29_L30insCRHPGPEPRSVC* VAF 1.39%, ASXL1 p.G645Vfs*58 VAF 1.55%, ASXL1 p.E929G VAF 1.46% ,ASXL1 p.T936= VAF 1.41%(Tier 1) Started R-HyperCVAD + dasatinib...In the current era of CML targeted therapy with TKIs or myristoyl inhibitors, the presence of associated genetic alterations (AGAs) becomes relevant, as they may predict aggressive behavior and open a window to evaluate transplantation in these patients for better therapeutic responses. Imatinib is not benefical in this patients."

Chronic Myeloid Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Herpes Zoster • Infectious Disease • Leukemia • Liver Failure • Musculoskeletal Pain • Myeloproliferative Neoplasm • Respiratory Diseases • Varicella Zoster • ABL1 • ASXL1 • CD20 • CEBPA • GATA2 • WT1

Impact of tyrosine kinase inhibitors on estimated glomerular filtration rate in chronic myeloid leukemia patients (ASH 2025) - "Conclusion Renal function remained stable in most CML patients on TKIs. However, dasatinib was associated with a significant eGFR decline, whereas imatinib and nilotinib showed no such effect."

Clinical • Acute Kidney Injury • Chronic Kidney Disease • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Nephrology • Renal Disease

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors (ASH 2025) - "Treatment before first discontinuation was imatinib in 58.9% (n=23), nilotinib in 30.8% (n=12), and dasatinib in 10.3% (n=4). All 39 patients were alive at the final follow-up. Conclusion These results demonstrate that a second TKI stop is feasible and the majority of patients regain DMR within 6 months."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • TFRC

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML (ASH 2025) - "Pt1: Male, CML diagnosed at age 21; prior TKIs: imatinib, dasatinib, bosutinib; progressed to CML-BC at age 26; no response to ponatinib in monotherapy after two months so asciminib was added for 1 months of combination therapy. The distinct yet complementary mechanisms of TKIs were well tolerated in pt 1 and 2; its use in patients older than 50 years could require caution moreover if precedently treated with nilotinib. These preliminary results warrant further confirmation in larger prospective trials."

Metastases • Chronic Myeloid Leukemia • Myocardial Infarction • ABL1

Chronic myeloid leukaemia in the pregnancy: Experience at a university hospital in Paraguay (ASH 2025) - "Nineteen cases of unplanned pregnancies were recorded while receiving TKIs: fifteen on imatinib and four on dasatinib. Management strould be more aggressive. The duration of prior TKI exposure and exposure during pregnancy may be the most determining factors for a successful delivery"

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase (ASH 2025) - "Asciminib was used in conjunction with another ATP-binding TKI in 5 (71%) patients (ponatinib, N=4; dasatinib, N=1); three of whom also received additional treatment (venetoclax and hypomethylating agents, N=2; intensive chemotherapy, N=1). Asciminib-based regimen was well tolerated, with only grade 1-2 non-haematological toxicities in 3 patients (hepatotoxicity, N=1; rash, N=1; myalgia, N=1) and grade 2 or above cytopenia in 3 patients.Conclusions The retrospective nature and small cohort size of our study notwithstanding, our analysis of this real-life cohort of CML-BP patients showed promising activity and reassuring safety profile of asciminib-based regimens. Patients experiencing ponatinib failure could potentially be salvaged by asciminib-based treatment."

Monotherapy • Chronic Myeloid Leukemia • Hematological Malignancies • Musculoskeletal Pain • ABL1

First report of real-word outcomes of chronic myeloid leukemia in Uruguay in tyrosine kinase inhibitor era (ASH 2025) - "No patient received nilotinib or bosutinib in 1L...Imatinib had the highest frequency of events (39.7%, mostly GI), followed by dasatinib (29.3%, mostly pleural effusion), and nilotinib (16.5%, mostly thrombocytopenia)...Although the disease follow-up could be biased, imatinib outcomes as 1L treatment was inferior to international reports, which suggest it can be improved with second generation TKI use in 1L, but cost and access could be an issue. OS are acceptable and similar to other reports, with significant differences according to known factors such as age, phase and risk."

Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Respiratory Diseases • Solid Tumor • Thrombocytopenia

Efficacy and safety of pegylated interferon alfa-2b combined with tyrosine kinase inhibitors in chronic Phase chronic myeloid leukemia patients with TKI resistance or intolerance (ASH 2025) - "Median follow-up was 72 weeks (range 24-96).Prior TKIs included imatinib, nilotinib, dasatinib, flumatinib,and olverembatinib.By June 30,2025.Sixteen, fourteen, ten, and eight patients completed therapy at weeks 24,48,72,and 96,respectively.Nine patients discontinued treatment due to adverse events.Molecular responses:Week 24: MMR 37.5% (6/16),DMR 6.3%(1/16),Week 48:MMR57.1% (8/14); Week 72: MMR40.0% (4/10); DMR 30.0% (3/10); Week 96: MMR 50.0% (4/8),DMR 25.0% (2/8).Safety:The most common AEs were flu-like symptoms and hematologic toxicities (predominantly grade 1-2).Dose reductions or extended dosing intervals (up to q2 weeks) of PEG IFNα-2b were implemented to manage AEs. Conclusion PEG IFNα-2b combined with TKIs significantly reduces BCR::ABL1 transcript levels, enabling patients with TKI-resistant or intolerant chronic-phase chronic myeloid leukemia (CP-CML) to achieve major molecular response (MMR) and even deep molecular response (DMR), with a favorable safety..."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • IFNA1

Feasibility of the edmonton symptom assessment system (ESAS) score as patient-reported outcomes (PROs) assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy: A pilot Study (ASH 2025) - "TKIs most frequently used before discontinuation were dasatinib (n=8 out of 27 pts, 30%), bosutinib (n=3/8, 37%), imatinib (n=3/5, 60%), nilotinib (n=2/6, 33%), and asciminib (n=2/27, 7%). Additionally, ESAS may be valuable for longitudinal follow-up to assess symptom evolution after treatment changes. Prospective studies with larger cohorts are warranted to validate these observations and determine whether symptom-guided strategies can improve TKI adherence and clinical outcomes in CML."

Clinical • Patient reported outcomes • Anorexia • Chronic Myeloid Leukemia • CNS Disorders • Depression • Hematological Malignancies • Leukemia • Mood Disorders • Palliative care

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003 (ASH 2025) - "This trial will use any of the following (based on patient/physician preference) during the consolidation treatment phase: asciminib 40 mg PO daily plus imatinib (maximum dose of 400 mg PO once daily), asciminib 40 mg PO bid plus nilotinib (maximum dose of 300 mg bid), asciminib 80 mg PO daily plus dasatinib (maximum dose of 100 mg daily), asciminib 80 mg PO daily. This is the first report of asciminib use to attempt 2 nd TFR. The combination was well tolerated, and patients were able to complete the combination phase. Preliminary results suggest feasibility and potential to increase cure for CML."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia

Poor survival and younger age in patients with blast Phase chronic myeloid leukemia in a developing country: A multicenter real-world study of 138 patients. (ASH 2025) - "The most frequently used TKI was Dasatinib (64% of pts)... This Peruvian cohort showed a younger age of presentation and poorer overall survival in blast phase CML. These outcomes may be related to limited healthcare resources, poor access to alternative TKIs, bone marrow transplantation, and delays in hospital care. This data shows the urgent need to improve national policies for access to innovative therapies that could improve the outcome of this dismal condition."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia

Mortality trends in chronic myeloid leukemia in the United States: A population-based analysis (ASH 2025) - "Discussion The substantial reduction in CML mortality over the past two decades aligns with the widespread adoption of TKIs, particularly imatinib (approved 2001). The subsequent approval of dasatinib (2006), nilotinib (2007), and bosutinib (2012) has aided in the transformation of CML from a fatal disease to a chronic condition for most patients...Males and White individuals face higher apparent mortality rates. The slight uptick in mortality from 2018 to 2020 may be related to the increased vulnerability of patients with hematologic malignancies to severe COVID-19 infection."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • ABL1 • BCR

Comparative 3- and 5-year outcomes among first-line imatinib, dasatinib, and nilotinib in chronic myeloid leukemia: A real world analysis (ASH 2025) - "Imatinib showed the most favorable survival at 3 and 5 years. Dasatinib was associated with higher mortality but lower diabetes risk, while nilotinib offered similar survival and a trend toward reduced hospitalizations. These results support personalized TKI selection in frontline CML therapy."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Coronary Artery Disease • Diabetes • Hematological Malignancies • Hypertension • Leukemia • Metabolic Disorders

Dasatinib as 2nd line treatment is safe and effective in peruvian CML patients: A multicentric real-world study (ASH 2025) - "Background: The second-generation tyrosine kinase inhibitor Dasatinib (DAS) used as second-line treatment is a valid option in patients with CML after resistance or intolerance to prior Imatinib (IMA). In this Peruvian real-life cohort we found that DAS as second-line treatment in CML patients is a safe and effective therapy with high RMM rate, low rates of G3-4 pleural effusion and a discontinuation rate similar to other studies, with 57.1% of pts remaining on treatment at the last follow-up. This data will help take actions to improve the outcomes of Peruvian CML patients."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Respiratory Diseases

A rare case of high-risk M4 Acute Myeloid Leukemia with ETV6::ABL1 rearrangement in a young adult with preceding chronic idiopathic thrombocytopenia: Insights and implications (ASH 2025) - "Treatment Course: The patient was treated per the AAML1831 protocol for high-risk disease, with the addition of Dasatinib due to potential Imatinib resistance in ETV6::ABL1-positive disease...The patient received a 10/10 HLA-matched unrelated donor allogeneic HSCT in May of 2024 with a Busulfan and Cyclophosphamide conditioning regimen... This report highlights an extremely rare case of AML with ETV6::ABL1 rearrangement in a young adult with prior idiopathic thrombocytopenia, successfully treated with a combination of AAML1831-based chemotherapy, Dasatinib, and allogeneic HSCT. Her disease course emphasizes the vital importance of advanced cytogenetic and molecular diagnostics in cytopenic patients, the tailored use of targeted therapies, and HSCT for rare high-risk rearrangements. Broader study of ETV6::ABL1 driven AML in children and adults is needed to establish the optimal management strategies and to better understand the significance of preceding cytopenias in..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Myelodysplastic Syndrome • Orthopedics • Thrombocytopenia • Thrombocytopenic Purpura • ABL1 • ETV6 • PHF6

Blinatumomab plus dasatinib in a dialysis-dependent patient with ph-positive B-ALL: Durable MRD-negative remission (ASH 2025) - "To date, the literature is limited to isolated reports of reduced-dose imatinib or dasatinib monotherapy in dialysis patients. After cycle 1 the patient achieved MRD-positive complete remission (BCR-ABL1/ABL1 ratio 0.019%, 3.6-log reduction). Following cycle 2, bone-marrow biopsy demonstrated MRD-negative complete remission with undetectable BCR-ABL1. Serial lumbar punctures remained negative."

Clinical • Minimal residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Kidney Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Mucositis • Nephrology • Renal Disease • Respiratory Diseases • Septic Shock • ABL1 • BCR • IKZF1